• Fri. Jan 22nd, 2021

Genitourinary Therapeutics Market 2021 Size, Top Countries Data, Growth Opportunities, Definition, Emerging Technologies, Trends, SWOT Analysis, Segments, Landscape and Demand by Forecast to 2025

REPORT HIGHLIGHT

The genitourinary therapeutics Market is estimated to represent a global market of USD 30.2 billion by 2025 with growth rate of 1.2%. The market covers the analysis of the commercial or pipeline therapeutics that can be used for genital and urinary organ treatment. Conditions such as Glomerulonephritis, Hemolytic uremic syndrome, Polycystic kidney disease and Hydronephrosis may damage kidney. Thus, it is advisable to treat these conditions at right time.

Download  Sample of This Strategic Report-https://www.kennethresearch.com/sample-request-10293960

Growing demand for genitourinary therapeutics in developed as well as developing regions drives the market growth. Emerging and leading genitourinary therapeutics are studies under the scope of this research study. Furthermore, undergoing clinical trials and patents are studies during the market estimation.Constant increase in number of pipeline therapeutics in this market segment boost the market growth to large level.

For example, in September 2016, Bristol-Myers Squibb collaborated with Nektar Therapeutics to assess the efficacy of NKTR-214 and Opdivo (nivolumab) in bladder cancer. Additionally, during the same time period, the company announced the validation of the Type II variation application for Opdivo (nivolumab) in the treatment of advanced bladder cancer by the European Medicines Agency.

The global market is categorized in terms of different indications like prostate cancer, benign prostatic hyperplasia, ovarian cancer, cervical cancer, renal cancer, erectile dysfunction, Urinary incontinence & overactive bladder, sexually transmitted diseases and others. In terms of revenue estimation, prostate and renal cancer was the market leading player as of 2016. Among which, renal cancer captured almost 26.11% share of the global revenue in 2016 whereas prostate cancer accounted for more than 20% share. Rising disease incidence in these segments coupled with continuous increase in therapeutic demand among patients drives the market growth in forecast period.

Based on products, the market studied in terms of anti-infective, urological, hormonal therapy drugs, and others. Hormonal therapy and urological segment is widely accepted products among the end user due to its high efficiency and cost effectiveness. Thereby, these segment captured largest revenue share, more than USD 12.0 billion of the global market.

Regionally, North American countries dominated the global market with the share of over 40% throughout the study period. Research and development initiatives by domiciled key players coupled with rising prevalence of genital and urinary diseases augment the overall revenue growth. Hormonal therapy drugs such as Casodex(Bicalutamide), Lupron(Leuprolide), Zoladex(Goserelin), Zytiga(Abiraterone), Xtandi(Enzalutamide), Eligard(Leuprolide) and Gonax(degaralix) widely used in these regions which helps the market to grow steadily.

Request For Full Report-https://www.kennethresearch.com/sample-request-10293960

On contrary, Asia Pacific region recorded highest CAGR of 6.2% during the forecast period. Increasing awareness level coupled with improving healthcare infrastructure supported the growth in Asia and Pacific countries like India, China and Japan. Also, increasing gynaecological diseases in developing regions will further boost the demand for drugs such as Doxil(Doxorubicin), Avycaz, Estrace and Estring, further support the market growth.

The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.

The years considered for the study are:

Historical Year – 2014 & 2015

Base Year – 2015

Estimated Year – 2016

Projected Year – 2025

TARGET AUDIENCE

Hospitals

Manufacturers

Traders, Distributors, And Suppliers

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY INDICATION

Prostate cancer

Benign prostatic hyperplasia

Ovarian cancer

Cervical cancer

Renal cancer

Erectile dysfunction

Urinary incontinence & overactive bladder

Sexually transmitted diseases

Others

MARKET, BY PRODUCTS

Anti-infective

Urological

Hormonal therapy drugs

Others

MARKET, BY REGION

North America

Europe

Asia Pacific

Rest of the World

MARKET,BY COUNTRY

Further Breakdown of The North America Market

U.S.

Canada

Further Breakdown of The Europe Market

Germany

France

Rest of Europe

Further Breakdown of The APAC Market

India

China

Rest of APAC

Further Breakdown of The Rest of the World Market

Middle East and Africa

Latin America

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Name: Kenneth research

Email:[email protected]

Phone: +1 313 462 0609

https://tokentimes.io/